Allergies, Gene Expression, Immune Response and Research

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

XTalks

NOVEMBER 6, 2020

The Burnaby, BC-based company developed the oral DNA-based vaccine using its proprietary bacTRL Gene Therapy Platform, which uses genetically modified bifidobacteria as carriers of genetic vaccine elements on a DNA plasmid. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials

Clinical Trials Clinical Trials Vaccination Vaccine

Tezepelumab granted Priority Review by U.S. FDA

The Pharma Data

JULY 8, 2021

executive vice president of Research and Development at Amgen. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles.(24,25) We lead with science through discovery research that is disease-agnostic and biology-first, modality-second.

Allergies

Allergies Trials In-Vivo Medicine

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

The Pharma Data

NOVEMBER 9, 2020

executive vice president of Research and Development at Amgen. Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.

Trials

Trials Production Sales Manufacturing

Clinical Research Informer

Symvivo’s Oral COVID-19 Vaccine Enters Clinical Trials

Tezepelumab granted Priority Review by U.S. FDA

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

Stay Connected